New Age Alpha Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

New Age Alpha Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$651K	Sell	11,380 -65,115	-85%	-$3.57M	0.03%	565
2026 Q1	$4.32M	Sell	76,495 -2,936	-4%	-$171K	0.2%	145
2025 Q4	$4.72M	Sell	79,431 -35,407	-31%	-$1.93M	0.2%	135
2025 Q3	$6.22M	Sell	114,838 -2,759	-2%	-$158K	0.26%	94
2025 Q2	$6.46M	Buy	117,597 +12,820	+12%	+$755K	0.28%	84
2025 Q1	$7.41M	Buy	104,777 +81,355	+347%	+$5.47M	0.33%	70
2024 Q4	$1.54M	Buy	+23,422	New	+$1.57M	0.06%	370

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

New Age Alpha Advisors's BMRN Position: Q2 2026 in Review

New Age Alpha Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 85% in Q2 2026, selling an estimated $3.57M and leaving 11,380 shares worth $651K. The position accounts for 0.03% of the portfolio, ranked #565.

New Age Alpha Advisors first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.41M in Q1 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

New Age Alpha Advisors held 11,380 shares of BioMarin Pharmaceuticals worth $651K as of Q2 2026.
New Age Alpha Advisors sold 65,115 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.57M.
BioMarin Pharmaceuticals made up 0.03% of New Age Alpha Advisors's portfolio in Q2 2026, its #565 holding.
New Age Alpha Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
New Age Alpha Advisors's BioMarin Pharmaceuticals position peaked at $7.41M in Q1 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on New Age Alpha Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.